Table 3.

Risks of symptomatic intracranial hemorrhage (SICH) with prestroke antiplatelet therapy

Characteristics	N	SICH rate, n (%)					Interaction P value*
		Antiplatelet users	Non-users	Crude OR	95% Cl	P value
Age
> 80 years	276	5 (5.2)	10 (5.6)	0.93	0.24-3.11	0.90	0.13
≤80 years	1,439	21 (6.1)	28 (2.6)	2.47	1.31-4.57	0.002
Sex
Male	1,054	16 (5.9)	18 (2.3)	2.68	1.26-5.66	0.005	0.25
Female	661	10 (5.8)	20 (4.1)	1.46	0.60-3.35	0.34
Diabetes mellitus
Yes	1,310	17 (5.7)	32 (3.2)	1.84	1.01-3.37	0.047	0.47
No	405	9 (6.3)	6 (2.3)	2.90	1.01-8.32	0.048
Baseline National Institutes of Health Stroke Scale (NIHSS) score
≤8	870	6 (3.1)	9 (1.3)	2.35	0.68-7.49	0.109	0.62
>8	845	20 (8.1)	29 (4.8)	1.74	0.91-3.26	0.066
Onset to treatment
≤3 hours	1,414	22 (5.9)	29 (2.8)	2.21	1.19-4.04	0.006	0.55
3-4.5 hours	301	4 (5.6)	9 (3.9)	1.46	0.32-5.45	0.54
Tissue plasminogen activator (TPA) dose
0.6 mg/kg	370	5 (4.2)	7 (2.8)	1.53	0.37-5.73	0.48	0.57
0.9 mg/kg	1,345	21 (6.5)	31 (3.0)	2.23	1.26-3.94	0.006
Prestroke statin
Yes	1,473	17 (6.0)	36 (3.0)	2.05	1.13-3.70	0.012	0.82
No	242	9 (5.7)	2 (2.4)	2.48	0.52-11.74	0.25

OR, odds ratio; CI, confidence interval.

^*Interaction effect between prestroke antiplatelet use and subgroups.